Shreyash Gugliya*
Diabetes mellitus (DM) is a diverse collection of metabolic diseases marked by persistently high blood sugar levels brought on by deficiencies in either the action or production of insulin, or production of insulin, or both. The international Diabetes Federation (IDF) estimates that approximately 537 million adults aged 20-79 years were living with diabetes in 2021 [1]. This epidemic poses significant public health challenges, including increased risk of cardiovascular disease, kidney failure, neuropathy, and retinopathy, leading to substantial morbidity and mortality. Diabetes is primarily classified into two main types: type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D is an autoimmune condition resulting in the destruction of insulin-producing beta cells in the pancreas, typically diagnosed in childhood or adolescence. In contrast, T2D, the more prevalent form of the disease, often develops in adulthood and is associated with insulin resistance and eventual beta-cell dysfunction. While lifestyle interventions such as diet and exercise remain fundamental in managing T2D, pharmacotherapy plays a critical role, particularly as the disease progresses [2].
The pharmacological management of diabetes has undergone significant evolution over the last few decades. Traditional therapies like insulin and sulfonylureas have been supplemented by newer classes of agents, each with distinct mechanisms of action, benefits, and safety profiles. Metformin, the cornerstone of T2D management, is praised not only for its glucose-lowering effects but also for its cardiovascular benefits and potential to aid in weight management. Meanwhile, the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors has transformed the treatment landscape by offering additional advantages, including weight loss and improved cardiovascular outcomes [3,4].
The recent focus on personalized medicine has further shifted the paradigm in diabetes management. Clinicians now consider individual patient characteristics, such as age, comorbidities, and preferences, when choosing pharmacotherapy. This tailored approach aims to maximize therapeutic efficacy while minimizing adverse effects. Moreover, advancements in technology, including continuous glucose monitoring (CGM) and insulin delivery systems, have enhanced patient engagement and glycemic control. Despite these advancements, challenges remain in achieving optimal glycemic control across diverse populations. Disparities in access to care, medication adherence, and health literacy continue to affect outcomes. Furthermore, ongoing research is exploring novel therapeutic targets, such as the gut microbiome, and the role of emerging agents like dual GIP and GLP-1 receptor agonists [5-7].
This review aims to provide an updated overview of the pharmacotherapy options available for diabetes mellitus, emphasizing the latest developments in drug classes, clinical evidence supporting their use, safety considerations, and future directions in diabetes management. By synthesizing current knowledge, this article aims to inform healthcare professionals and enhance the understanding of effective diabetes management strategies in the ever-evolving landscape of pharmacotherapy [8-10].
TYPES OF DIABETES MELLITUS
Diabetes mellitus (DM) includes several types, each with distinct characteristics and management strategies. Type 1 diabetes (T1D) is an autoimmune condition that results in the destruction of insulin-producing beta cells in the pancreas, typically diagnosed in childhood or adolescence, necessitating lifelong insulin therapy.
In contrast, Type 2 diabetes (T2D), which accounts for the majority of diabetes cases, is characterized by insulin resistance and a gradual decline in insulin production, often linked to obesity and sedentary lifestyles, with management focused on lifestyle changes and various oral and injectable medications [11,12].
Gestational diabetes mellitus (GDM) occurs during pregnancy and is marked by glucose intolerance that develops when the body cannot accommodate the increased insulin demands, requiring careful monitoring and management to protect both maternal and fetal health. Additionally, rare forms of diabetes, such as Maturity Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA), present unique challenges and are often misdiagnosed, necessitating tailored therapeutic approaches. Understanding these diverse types of diabetes is essential for effective treatment and prevention of complications [13].
Figure 1: Types of Diabetes Mellitus
CURRENT UPDATE OF PATHOLOGY: DIABETES MELITUS
Over the past 160 years, significant focus on the morphological and clinical aspects of diseases has resulted in established diagnostic criteria and a standardized nomenclature for efficiently describing changes linked to newly identified conditions. Diagnoses are made based on specific genotypic and phenotypic characteristics of patients, which indicate a predictable disease course and help optimize treatment by comparing outcomes among similarly affected individuals. In clinical medicine, the diagnosis of a disease becomes a key factor in managing patient care, guiding the daily operations of clinics and hospitals across the country. Pathologists play a crucial role in integrating clinical, gross, morphological, and molecular data to provide a coherent and accurate diagnosis. Signs and symptoms are identified through patient examination, and the clinical team, including the pathologist, develops a differential diagnosis based on these findings. The subsequent evaluation often involves gathering patient history, conducting physical exams, performing imaging studies, analyzing bodily fluids (such as blood, urine, sputum, and stool), and potentially obtaining tissue biopsies [14].
A NEW THERAPY FOR TYPE FIRST DIABETES MELITUS
Recent studies indicate that ongoing research at the Harvard Stem Cell Institute (HSCI) may lead to new treatments for Type 1 Diabetes Mellitus (T1D). The Melton Lab at Vertex Pharmaceuticals has developed VX-880, an investigational therapy involving the replacement of pancreatic islet cells, which shows promise when combined with immunosuppressive therapy. In a Phase 1/2 clinical trial, the first patient treated with a single infusion of VX-880 administered at half the target dose experienced significant restoration of islet cell function by Day 90. This patient, diagnosed with T1D 40 years ago and reliant on exogenous insulin, achieved successful engraftment and showed rapid improvements across multiple clinical measures [15].
Vertex Pharmaceuticals is a global biotechnology firm dedicated to scientific innovation aimed at creating transformative treatments for serious diseases. The company has several approved therapies addressing the root causes of cystic fibrosis (CF), a rare and life-threatening genetic condition, and it is actively engaged in various clinical and research initiatives in CF [16-18]. Additionally, Vertex has a strong pipeline of investigational therapies, including small molecules, mRNA, cell and genetic therapies (such as gene editing), targeting other severe conditions where it has deep insights into human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, Type 1 diabetes, and alpha-1 antitrypsin deficiency [19-21].
10.5281/zenodo.15038248